Results 31 to 40 of about 21,166 (196)
Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]
, 2015 Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján +2 more
core +1 more source
Rupture of hepatocellular carcinoma after transcatheter arterial chemoembolization: A case report
International Journal of Gastrointestinal Intervention, 2021 Transcatheter arterial chemoembolization (TACE) is one of the most common treatment options for patients with unresectable hepatocellular carcinoma (HCC). HCC rupture following TACE is a rare but potentially life-threatening complication.
Hye Hyeon Moon, Hee Ho Chu, Ji Hoon Shin
doaj +1 more source
Universa Medicina, 2016 BACKGROUND Hepatocellular carcinoma (HCC) incidence is increasing in Asia and Africa. Locoregional minimally invasive transarterial chemoembolization (TACE) is the palliative therapy of choice, improving survival rate. Adequate lipiodol dose calculation in TACE is necessary to produce good therapeutic effect. Lipiodol retention pattern can predict TACE
Margaretha Vianny +2 more
openaire +4 more sources
Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies [PDF]
, 2019 Background and Aims: While transarterial chemoembolization (TACE) represents a standard of therapy for intermediate-stage hepatocellular carcinoma (HCC) and is also routinely performed in patients with liver metastases, it is still debated which ...
Bruners, Philipp +7 more
core +1 more source
Embolization in an adrenocortical carcinoma as palliative therapy [PDF]
, 1999 Background: With an annual incidence of 0.2% of new cases per 100,000 inhabitants, adrenocortical carcinoma is rare. In advanced tumor only palliative treatment modalities are practicable. Because of scarcity of the tumor, standard treatment has not been
Braunschweig, R. +5 more
core +1 more source
World Journal of Gastroenterology, 2014 To identify factors affecting early local recurrence after transcatheter arterial chemoembolization (TACE) and investigate treatments and outcomes for local recurrence.Early local recurrence and no early local recurrence groups drawn from 134 patients who were initially diagnosed with hepatocellular carcinoma (HCC) and showed a complete response (CR ...
Woo Sun, Rou +5 more
openaire +2 more sources
Metformin: a modulator of bevacizumab activity in cancer? A case report. [PDF]
, 2015 Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic
Aliberti, C +7 more
core +1 more source
World Journal of Gastroenterology, 2016 Hepatocellular carcinoma (HCC) is one of the major causes of morbidity and mortality in patients with chronic liver disease. Transarterial chemoembolization (TACE) can significantly improve the survival rate of patients with HCC and is the first treatment choice for patients who are not suitable for surgical resections.
Ke, Yang +4 more
openaire +2 more sources
Open Life Sciences, 2018 Hepatocellular carcinoma is one of the leading causes of cancer-related death. Hepatic transcatheter arterial chemo-embolization (TACE) is commonly used clinically for advanced hepatocellular carcinoma treatment.
Wu Tao +7 more
doaj +1 more source
International Journal of Gastrointestinal Intervention, 2020 Super-selective lipiodol balloon-occluded transarterial chemoembolization (SSLB-TACE) increases lipiodol accumulation in the targeted nodule. To understand the mechanism of increased accumulation, it is necessary to understand intra-hepatic collateral ...
Toshiyuki Irie +2 more
doaj +1 more source